PL3625259T3 - Przeciwciała anty-sirpalfa - Google Patents
Przeciwciała anty-sirpalfaInfo
- Publication number
- PL3625259T3 PL3625259T3 PL18729328.7T PL18729328T PL3625259T3 PL 3625259 T3 PL3625259 T3 PL 3625259T3 PL 18729328 T PL18729328 T PL 18729328T PL 3625259 T3 PL3625259 T3 PL 3625259T3
- Authority
- PL
- Poland
- Prior art keywords
- sirpalpha
- antibodies
- sirpalpha antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17171285 | 2017-05-16 | ||
| PCT/EP2018/062473 WO2018210793A2 (en) | 2017-05-16 | 2018-05-15 | ANTI-SIRPα ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3625259T3 true PL3625259T3 (pl) | 2024-08-12 |
Family
ID=58714966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18729328.7T PL3625259T3 (pl) | 2017-05-16 | 2018-05-15 | Przeciwciała anty-sirpalfa |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11274159B2 (pl) |
| EP (2) | EP3625259B1 (pl) |
| JP (1) | JP7171617B2 (pl) |
| KR (1) | KR102714600B1 (pl) |
| CN (2) | CN118271443A (pl) |
| AR (1) | AR111630A1 (pl) |
| AU (1) | AU2018268304B2 (pl) |
| BR (1) | BR112019023754A2 (pl) |
| CA (1) | CA3063622A1 (pl) |
| CL (1) | CL2019003266A1 (pl) |
| DK (1) | DK3625259T3 (pl) |
| ES (1) | ES2981193T3 (pl) |
| FI (1) | FI3625259T3 (pl) |
| HR (1) | HRP20240924T1 (pl) |
| HU (1) | HUE067040T2 (pl) |
| LT (1) | LT3625259T (pl) |
| MX (1) | MX2019013749A (pl) |
| MY (1) | MY199247A (pl) |
| PL (1) | PL3625259T3 (pl) |
| PT (1) | PT3625259T (pl) |
| RU (1) | RU2771174C2 (pl) |
| TW (1) | TWI710574B (pl) |
| WO (2) | WO2018210793A2 (pl) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2990971T3 (es) | 2016-04-14 | 2024-12-02 | Ose Immunotherapeutics | Nuevos anticuerpos anti-SIRPa y sus aplicaciones terapéuticas |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| US11779642B2 (en) | 2016-12-09 | 2023-10-10 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| JP7337099B2 (ja) | 2018-05-25 | 2023-09-01 | アレクトル エルエルシー | 抗ｓｉｒｐａ抗体およびその使用法 |
| EA202190138A1 (ru) * | 2018-06-29 | 2021-05-27 | ЭЛЕКТОР ЭлЭлСи | Анти-sirp-бета1 антитела и способы их использования |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| JP7451520B2 (ja) * | 2018-11-15 | 2024-03-18 | ビョンディス・ビー．ブイ． | ヒト化抗ＳＩＲＰα抗体 |
| WO2020247820A1 (en) | 2019-06-07 | 2020-12-10 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| JP7295283B2 (ja) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| AU2020394204A1 (en) | 2019-11-27 | 2022-06-02 | ALX Oncology Inc. | Combination therapies for treating cancer |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| WO2021129697A1 (en) * | 2019-12-24 | 2021-07-01 | Lanova Medicines Limited Company | ANTI-SIRPα MONOCLONAL ANTIBODIES AND USES THEREOF |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| EP4528281A3 (en) * | 2020-02-20 | 2025-06-18 | Universiteit Maastricht | Detection method of circulating bmp10 (bone morphogenetic protein 10) |
| AU2021283083A1 (en) | 2020-06-01 | 2022-12-01 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| CN114560940B (zh) * | 2020-11-27 | 2023-07-14 | 缔码生物科技(武汉)有限公司 | 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用 |
| EP4253416A4 (en) * | 2020-11-30 | 2024-11-13 | Qure Biotechnology (Shanghai) Co., Ltd. | ANTI-SIRPALPHA ANTIBODY OR ASSOCIATED ANTIGEN-BINDING FRAGMENT, AND USE THEREOF |
| JP2023552375A (ja) | 2020-12-06 | 2023-12-15 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体 |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| US11572412B2 (en) * | 2021-06-04 | 2023-02-07 | Boehringer Ingelheim International Gmbh | Anti-SIRP-alpha antibodies |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4389767A1 (en) * | 2021-08-17 | 2024-06-26 | Hangzhou Jiuyuan Gene Engineering Co., Ltd | Monoclonal antibody targeting sirp? and use thereof |
| MX2024002527A (es) * | 2021-09-03 | 2024-05-10 | Zymeworks Bc Inc | Variante fc con alta estabilidad termica y funcion efectora atenuada. |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| JP2025523369A (ja) | 2022-06-01 | 2025-07-23 | エーエルエックス オンコロジー インコーポレイテッド | 尿路上皮癌腫を治療するための併用療法 |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120202222A (zh) | 2022-11-16 | 2025-06-24 | 勃林格殷格翰国际有限公司 | 抗SIRPa抗体的疗效预测性生物标志物 |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR20250167002A (ko) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Kras 조절 화합물 |
| WO2024220895A1 (en) * | 2023-04-20 | 2024-10-24 | Twist Bioscience Corporation | Antibodies and variant nucleic acid libraries for sirp-alpha |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| CN116715774B (zh) * | 2023-05-12 | 2023-11-24 | 武汉爱博泰克生物科技有限公司 | 针对人axl的兔单克隆抗体及其制备方法和应用 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN118344476B (zh) * | 2024-05-16 | 2024-11-15 | 武汉爱博泰克生物科技有限公司 | 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用 |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118620078B (zh) * | 2024-07-09 | 2024-11-19 | 武汉爱博泰克生物科技有限公司 | 抗人cd45ra蛋白的抗体、抗体偶联物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2001040307A1 (de) * | 1999-11-30 | 2001-06-07 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper gegen signal-regulator-proteine |
| JP2008505174A (ja) | 2004-07-15 | 2008-02-21 | ゼンコー・インコーポレイテッド | 最適化Ｆｃ変異体 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| ES2714716T3 (es) * | 2011-01-19 | 2019-05-29 | Cantargia Ab | Anticuerpos anti-IL1RAP y su uso para el tratamiento de tumores sólidos |
| US20140242095A1 (en) * | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| EP2834273B1 (en) * | 2012-04-05 | 2018-08-22 | F.Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| KR102677704B1 (ko) * | 2012-05-30 | 2024-06-21 | 추가이 세이야쿠 가부시키가이샤 | 표적 조직 특이적 항원 결합 분자 |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP3116544A4 (en) * | 2014-03-11 | 2017-08-23 | The Board of Trustees of the Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| DK3298043T3 (da) * | 2015-05-18 | 2021-02-15 | Ab Initio Biotherapeutics Inc | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse |
| ES3032613T3 (en) | 2015-10-21 | 2025-07-22 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| EP3443010B1 (en) * | 2016-04-14 | 2024-08-07 | Ose Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
| US10611842B2 (en) * | 2016-08-03 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy |
-
2018
- 2018-05-15 US US16/614,199 patent/US11274159B2/en active Active
- 2018-05-15 CN CN202410367469.2A patent/CN118271443A/zh active Pending
- 2018-05-15 MX MX2019013749A patent/MX2019013749A/es unknown
- 2018-05-15 CN CN201880032714.7A patent/CN110799536B/zh active Active
- 2018-05-15 BR BR112019023754A patent/BR112019023754A2/pt unknown
- 2018-05-15 EP EP18729328.7A patent/EP3625259B1/en active Active
- 2018-05-15 ES ES18729328T patent/ES2981193T3/es active Active
- 2018-05-15 FI FIEP18729328.7T patent/FI3625259T3/fi active
- 2018-05-15 HR HRP20240924TT patent/HRP20240924T1/hr unknown
- 2018-05-15 CA CA3063622A patent/CA3063622A1/en active Pending
- 2018-05-15 EP EP24169594.9A patent/EP4400173A3/en active Pending
- 2018-05-15 PL PL18729328.7T patent/PL3625259T3/pl unknown
- 2018-05-15 PT PT187293287T patent/PT3625259T/pt unknown
- 2018-05-15 RU RU2019141289A patent/RU2771174C2/ru active
- 2018-05-15 LT LTEPPCT/EP2018/062473T patent/LT3625259T/lt unknown
- 2018-05-15 WO PCT/EP2018/062473 patent/WO2018210793A2/en not_active Ceased
- 2018-05-15 MY MYPI2019006658A patent/MY199247A/en unknown
- 2018-05-15 WO PCT/EP2018/062477 patent/WO2018210795A1/en not_active Ceased
- 2018-05-15 DK DK18729328.7T patent/DK3625259T3/da active
- 2018-05-15 TW TW107116450A patent/TWI710574B/zh active
- 2018-05-15 KR KR1020197037055A patent/KR102714600B1/ko active Active
- 2018-05-15 HU HUE18729328A patent/HUE067040T2/hu unknown
- 2018-05-15 JP JP2019563581A patent/JP7171617B2/ja active Active
- 2018-05-15 AU AU2018268304A patent/AU2018268304B2/en active Active
- 2018-05-16 AR ARP180101300A patent/AR111630A1/es not_active Application Discontinuation
-
2019
- 2019-11-14 CL CL2019003266A patent/CL2019003266A1/es unknown
-
2022
- 2022-02-02 US US17/591,231 patent/US11718681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268517A (en) | Anti-tigit antibodies | |
| ZA201905966B (en) | Anti-lag3 antibodies | |
| IL267797B1 (en) | Anti-gpc3 antibody | |
| SG11202000660QA (en) | Anti-tigit antibodies | |
| LT3625259T (lt) | Anti-sirpalfa antikūnai | |
| ZA202002141B (en) | Anti-transthyretin antibodies | |
| GB201709808D0 (en) | Antibodies | |
| IL273393A (en) | New epsilon anti-CD3 antibodies | |
| GB201601073D0 (en) | Antibodies | |
| SG10201914130VA (en) | GARP-TGF-β ANTIBODIES | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| GB201610044D0 (en) | Antibodies | |
| GB201616699D0 (en) | Antibodies | |
| ZA202103456B (en) | Anti-alpha-synuclein antibodies | |
| GB201603291D0 (en) | Antibodies | |
| GB201720970D0 (en) | Antibodies | |
| IL271067A (en) | Anti-trkb antibodies | |
| IL273529A (en) | Anti-PACAP antibody | |
| PT3484921T (pt) | Anticorpos anti-il-22r | |
| GB201711785D0 (en) | Antibodies | |
| GB201717006D0 (en) | Anti-OPG antibodies | |
| GB201709818D0 (en) | Antibodies | |
| GB201703071D0 (en) | Antibodies | |
| GB201701416D0 (en) | Anti-OPG antibodies | |
| GB201709592D0 (en) | Antibody |